A machine learning system has been developed to identify cancer cells based on their light scattering patterns, achieving high accuracy even with cells having similar morphology. The system, which uses dark-field microscopy and machine learning algorithms, has shown promise in distinguishing between different types of cancer cells.
The study validated the Cancer Stigma Scale (CASS) in the Greek context, examining its relationship with attitudes toward mental illness. The Greek CASS demonstrated high internal consistency and construct validity, with moderate correlations between cancer stigma and attitudes toward mental illness.
A meta-analysis of 21 randomized controlled trials involving 8449 participants found that structured exercise was associated with significant improvements in overall survival and reduced risk of cancer recurrence. The benefits were strongest among participants who completed at least 70% of their exercise program.
St. Jude Children's Research Hospital is ranked third among the best pediatric cancer hospitals in the US, reflecting its commitment to advancing care and improving outcomes for children with cancer. The hospital has been recognized for its dedication to research and clinical care, with top survival rates for childhood cancers.
A new 3D-structure study reveals BRD4's unexpected ability to bind to chromosomes without a molecular signal, shedding light on its role in cancer and potential treatments. The discovery could lead to a better understanding of BRD4's function and its interaction with other proteins.
UCLA researchers are launching a phase 1/2 clinical trial to evaluate the safety and efficacy of JAK inhibitors in preventing immune checkpoint inhibitor-induced type 1 diabetes. The trial aims to test whether these drugs can protect insulin-producing cells in patients who develop diabetes after cancer immunotherapy.
The PAPILLON trial demonstrates durable clinical benefit and longest median overall survival reported to date for people with lung cancer carrying an EGFR exon 20 insertion mutation. Amivantamab plus chemotherapy extended overall survival by a clinically meaningful 6 months and cut disease progression risk by 60%.
Oben Health's AI-enabled platform brings preventive care to underserved communities through trusted community spaces. Malama Health's digital maternal health mobile app also receives recognition for its impact on maternal health outcomes.
A new AI tool has been developed to predict treatment and survival outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy. The tool consistently outperformed standard clinical biomarkers, achieving high accuracy scores in predicting survival outcomes.
A multicenter qualitative study identified key differences in palliative care and oncology teams, affecting end-of-life patient outcomes. The findings highlight the importance of high-quality care for patients with cancer during hospice transitions.
Researchers identified ANKRD11 as a key regulator that suppresses CD8+ T cell activity during chronic hepatitis B virus infection and cancer. ANKRD11 deficiency reprograms CD8+ T cell differentiation to enhance immunity in chronic infection and cancer, making it a potential therapeutic target.
A Phase 1 study showed the investigational therapy demonstrated a manageable safety profile, with 33.3% of patients achieving objective response at the recommended 2.5mg/kg dose. The treatment was well-tolerated, with no treatment-related deaths and only one patient discontinuing due to an adverse event.
Results from the DeLLphi-309 study suggest that extended-interval dosing regimens of tarlatamab may offer patients greater treatment flexibility while maintaining comparable clinical activity. The study found improved overall survival rates with less frequent dosing schedules, but with similar treatment-emergent adverse event rates.
The phase 1b DeLLphi-308 study found that subcutaneous tarlatamab achieved serum exposures comparable to the approved intravenous dosing while maintaining a favorable safety profile, with 30% preliminary objective response rate in patients with ES-SCLC.
A new review in Science Bulletin outlines how multimodal AI can integrate molecular, cellular, and clinical data to refine treatment choices and predict side effects. The approach aims to address challenges in cancer treatment, including primary resistance and immune-related adverse events.
Researchers found that chemotherapy and radiotherapy treatments change the genetic mutations in normal tissue, giving some cells an advantage. The study suggests that sequencing normal tissue from cancer patients could help understand how genes regulate tissue response to drugs and minimize damage to normal tissues.
Researchers at CU Anschutz have developed CAR T-cell therapy to target two pathways that help colorectal tumors grow and evade the immune system, B7-H3 and IL-8. The therapy aims to provide a more durable response than traditional chemotherapy.
Scientists have identified a pathway in liver cells that may explain how statins could help prevent or slow the development of liver cancer associated with fatty liver disease. Statins reduced levels of GGPP, a molecule that helps activate Rho GTPases, proteins involved in regulating a cell's internal structure and signaling.
ESMO has launched a funding program to support academic clinical research aimed at optimizing cancer care pathways. The program will fund studies addressing treatment optimization, streamlined delivery, and patient-centered care, with a focus on improving patient outcomes and healthcare sustainability.
Salk Institute researchers have discovered a novel pathway that links chronic interferon II exposure to mitochondrial dysfunction, leading to immunosuppression and enhanced tumor growth. By blocking prostaglandin E2, they found a viable target to restore immune system function and combat immunotherapy resistance.
A new survey by the National Comprehensive Cancer Network (NCCN) reveals that 100% of cancer centers in the US are experiencing a shortage for at least one anti-cancer agent, with 94% noting a shortage of ifosfamide. The survey also found that 71% of centers are experiencing a shortage of carboplatin, a key chemotherapy used to treat v...
A new case report describes a 68-year-old woman with stage IV lung adenocarcinoma who developed severe hemolysis after receiving pembrolizumab, despite a negative Coombs test. The patient's hemoglobin declined from 11-12 g/dL to 6.4 g/dL, and laboratory markers of hemolysis improved with corticosteroid treatment. The case highlights th...
Researchers found that chemotherapy drugs like cisplatin and carboplatin can leave characteristic mutations in healthy liver tissue of children, potentially increasing the risk of future cancers. The study used advanced sequencing technology to detect mutations in non-cancerous tissues from pediatric cancer patients.
Researchers explored strategies to restore MHC-I expression in CNS cancers to make them more visible to the immune system. Approaches include epigenetic therapies, AAV vectors, PCSK9 inhibition, and modifying the tumor microenvironment. However, efficient delivery, antigen processing, and a limited neoantigen repertoire remain signific...
A study from the University of Cologne identified a critical dependency in small cell lung cancer that can be exploited therapeutically. Targeted inhibition of the NMD pathway offers a promising approach to treat SCLC by accumulating mutated proteins and presenting abnormal peptides on the cell surface, making it detectable to the immu...
Two nanomedicine projects will be developed to combat cancer, with the first focusing on cholangiocarcinoma and the second on ovarian cancer. The projects will utilize intelligent nanomedicines capable of adapting to individual tumor characteristics and energy supply, with the goal of more precise and effective therapies.
New research reveals a significant increase in stroke risk within 3 months of cancer diagnosis, with pancreatic and lung cancers showing the highest rates. The study, published in CANCER, found that younger patients and those with advanced cancer are particularly at risk.
A novel laser-fabricated plasmonic chip combines 185 nm Raman resolution with deep learning to identify and sort cancer cells. The developed sorter achieves precise cell sorting without labeling, using spatially resolved Raman signals.
Massey researchers will evaluate TROP2 targeted ADCs for breast and pancreatic cancer care, aiming to identify predictive biomarkers and therapeutic strategies. The grant will help develop a test to predict patient drug response and identify secondary treatments for resistant tumors.
UCLA scientists develop a stem cell-based platform to produce uniform T cells that target solid tumors in a unique way, avoiding a common side effect. The therapy, called AlloESO-T cells, keeps tumors in check and extends survival in mouse models of ovarian, melanoma, and prostate cancers.
Researchers developed a new treatment for acute myeloid leukemia (AML) by using AcTor, a molecule that inhibits a signalling protein, in combination with ixazomib. The treatment successfully eliminated cancer cells and leukemic stem cells, showing promising results in mice studies.
Researchers develop innovative masking technology to deliver antibodies directly into brain cells, targeting proteins inside cells. The technology, called SL4, enables antibodies to reach previously inaccessible targets, opening new possibilities for treating diseases like Parkinson's and cancer.
Researchers discovered that cancer cells with RET mutations produce higher levels of the OPG protein, which disrupts bone renewal and blocks destruction, favoring bone accumulation. Measuring OPG levels via blood tests could identify and monitor patients with aggressive disease.
A new method uses hybrid bright-dark field imaging to enhance digital pathology resolution, improving diagnostic sensitivity and AI-assisted analysis. It achieves 2.1x spatial resolution enhancement with minimal hardware upgrades and improved efficiency.
A new study reveals that inhibitory brain circuits can suppress adult glioma growth by reducing calcium activity inside tumor cells. Inhibitory neurons form synaptic contacts with glioma cells and reduce tumor cell proliferation and survival in preclinical models.
Researchers discovered a bacterium in urine that can convert DHEA into testosterone, shedding light on a previously unknown microbial route to a hormone central to prostate biology. This finding raises new questions about the potential role of microorganisms near the prostate in shaping its chemical environment.
Dr. Amir Iravani brings expertise in molecular imaging and radiopharmaceutical therapy to UCLA Health, expanding research and clinical cancer care. He aims to integrate theranostics into cancer care, expand clinical trials, and develop new treatments for solid tumors and hematologic malignancies.
Mantle cell lymphoma treatment may be improved by considering a patient's biology and risk level, rather than age alone. High-risk patients can be identified at diagnosis and treated with targeted therapies, while low-risk patients may receive less intensive treatment.
Researchers found that patients with lung cancer had more detectable microplastics and higher microplastic burdens in their lung wash and tissue samples. The study suggests a link between microplastics and lung disease, with polypropylene and polyethylene being the most common types of plastic.
Cancer cells release natural antioxidants, such as Peroxiredoxin 1, to suppress immune-cell activity and prevent destruction. Removing this antioxidant production enhances the cancer's response to immunotherapy.
A new Drexel-led study introduces a culinary medicine program for caregivers of children with cancer, which improves nutrition and overall well-being. The program combines live virtual culinary workshops and individualized coaching to help families address treatment-related nutrition challenges.
The Starr Healthspan Innovation Alliance will bridge the gap between scientific discovery and life-changing treatments for age-related diseases. The partnership will expand clinical trials and support groundbreaking laboratory research to extend healthy lifespan.
Researchers found that psilocybin durably prevented chemotherapy-induced peripheral neuropathy in mice, preserving nerve function and tumor-killing effects. The study's findings have potential disease-modifying approaches to chronic pain and may reframe CIPN as a failure of resilience that can be addressed with early intervention.
A review led by UCLA investigators found that AI can identify subtle signs of breast cancers missed during routine mammograms, but its clinical benefit is uncertain. AI may also identify patterns associated with an increased risk of cancer before it becomes visible on a mammogram.
Researchers discovered that cancer cells use an antioxidant protein to suppress T cells, allowing them to evade the immune system. This finding identifies a promising new target for cancer immunotherapy, potentially helping to overcome treatment resistance and improve patient outcomes.
A phase 2 clinical trial found that a less-intensive combination of azacitidine and venetoclax was more effective in treating acute myeloid leukemia, with patients tolerating treatment better and spending less time in the hospital. The combination also led to more patients reaching stem cell transplantation.
Researchers at IIT Gandhinagar develop a gold nanorod-based platform for ER-targeted cancer treatment, combining targeted drug delivery with photothermal therapy. The approach induces ER stress-mediated autophagy and apoptosis in cancer cells.
Researchers at the University of Basel have developed new drug combinations for liver cancer using mini-tumors, which retained key characteristics of the original tumor. The study identified several potent anti-tumor effects and combination therapies that could be effective despite significant biological differences between tumors.
The Huntsman Cancer Institute in Vineyard marks the start of vertical construction, aiming to ease travel burden for cancer patients in Utah County and beyond. The 284,000-square-foot campus will expand comprehensive cancer care, research, education, and innovation services.
Researchers found that meal timing programs the liver's daily rhythms and can have serious metabolic and health consequences when out of sync. The liver uses food signals to activate metabolic pathways, which can conflict with the body's natural circadian clock, leading to health issues.
A new class of KRAS inhibitors has shown at least as much potential as FDA-approved MEK inhibitors in shrinking NF1 tumors, preventing new ones from forming, and extending survival in mice. The treatment has the potential to be less severe in terms of side effects, making it an attractive alternative or replacement for MEK inhibitors.
A new study found that men with nonmetastatic prostate cancer who replaced saturated and animal fats with unsaturated and plant-based fats had a lower risk of death. Replacing about 10% of daily calories from animal fat with plant-based fat was associated with a 16% lower rate of death.
A new Cornell University study found that folic acid does not increase toxic formaldehyde or DNA damage in the body, providing reassurance for cancer patients taking high doses. The study, published in EMBO Molecular Medicine, used blood samples from nine patients taking high dose folic acid and 15 patients not taking the supplement.
A recent study shows how advanced optical imaging can reveal the metabolic activity of individual immune cells within a complex blood sample. Machine-learning algorithms were used to determine whether metabolic measurements alone could identify different immune-cell populations and detect immune activation.
MRI revealed rare cervical cancer spread into the uterine corpus, which was confirmed by histopathology. The unusual pattern created diagnostic challenges and required careful individual assessment. The study highlights the importance of recognizing less typical imaging features in evaluating suspected cervical malignancy.
Four outstanding oncology professionals receive 2026 ESMO awards for their contributions to cancer research, clinical care, and community leadership. The awards recognize pioneering work in cancer prevention, early detection, and immunotherapy.
Advances in blood cancer treatment have saved 25.8 million life-years, with significant gains for Hodgkin lymphoma and non-Hodgkin lymphoma patients. However, Black patients and those with acute myeloid leukemia (AML) continue to experience worse outcomes, highlighting the need for continued research investment.
Tumor-derived extracellular vesicles exhibit intrinsic organotropism and participate in establishing premetastatic niches, making them promising vehicles for targeted imaging probe delivery. However, current imaging approaches have limitations, including difficulty distinguishing between tumor-derived EVs and normal host cell-derived EVs.
Researchers found that melanoma cells suppress LL-37 production in neighboring keratinocytes, weakening a local epithelial defense pathway. This mechanism, mediated by melanoma-derived exosomal signals, can be targeted for therapeutic strategies.
A new study found that laws requiring notification of dense breast tissue led to modest increases in follow-up imaging tests, while insurance mandates had a significant impact, increasing ultrasound use four times. This study examined the influence of notification laws and insurance coverage independently.